Most sold healthcare stocks in Q4 2016

See which Healthcare stocks institutional investors trimmed or exited the most in Q4 2016, measured as net reductions in reported share positions from Q3 2016 into Q4 2016. Notable reductions at the top of this list include TEVA PHARMACEUTICAL-SP ADR (TEVA), MERCK & CO. INC. (MRK), ELI LILLY & CO (LLY), BAXTER INTERNATIONAL INC (BAX). These rankings are based on SEC 13F filings from the investors we track.

SymbolNameNet sharesNet valueNewAddedTrimmedSold outHolding now
TEVATEVA PHARMACEUTICAL-SP ADR-14,347,458-$735.47K13015
MRKMERCK & CO. INC.-5,876,326-$433.63K04329
LLYELI LILLY & CO-4,679,939-$391.62K03114
BAXBAXTER INTERNATIONAL INC-4,155,855-$388.79K00607
ZTSZOETIS INC-2,648,157-$120.83K01214
HCAHCA HEALTHCARE INC-1,906,333-$146.02K00131
UHSUNIVERSAL HEALTH SERVICES-B-1,787,999-$227.46K01203
DVADAVITA INC-1,757,878-$189.90K30125
UNHUNITEDHEALTH GROUP INC-1,441,564$285.05K256013
OPKOPKO HEALTH INC-1,412,757-$14.96K00010
ABBVABBVIE INC-1,251,111-$79.39K224010
RMDRESMED INC-1,036,300-$68.20K00101
PFEPFIZER INC-974,356-$3.27M137013
PHGKONINKLIJKE PHILIPS NVR- NY-953,503-$27.43K00202
EWEDWARDS LIFESCIENCES CORP-747,917-$171.09K00202
BKDBROOKDALE SENIOR LIVING INC-727,824-$22.88K00111
NVONOVO-NORDISK A/S-SPONS ADR-705,884-$109.36K01102
EXELEXELIXIS INC-557,940-$4.36K00101
PTCTPTC THERAPEUTICS INC-552,700-$7.74K00010
GERNGERON CORP-515,380-$1.19K00011
CTLTCATALENT INC-489,900-$12.66K00010
PDCOPATTERSON COS INC-484,528-$74.58K13125
BRKRBRUKER CORP-400,800-$9.12K00101
AMGNAMGEN INC-390,875-$107.89K12318
BIIBBIOGEN INC-390,313-$223.81K21327
PACBPACIFIC BIOSCIENCES OF CALIF-374,900-$3.36K00010
EXASEXACT SCIENCES CORP-365,300-$6.78K00010
PODDINSULET CORP-343,400-$14.47K00101
LFCRLIFECORE BIOMEDICAL INC-337,570-$4.21K10102
ESPRESPERION THERAPEUTICS INC-318,800-$4.42K00010
EBSEMERGENT BIOSOLUTIONS INC-294,600-$8.13K00101
PBHPRESTIGE CONSUMER HEALTHCARE-288,600-$12.43K00101
PINCPREMIER INC-CLASS A-280,837-$12.05K11103
SGMOSANGAMO THERAPEUTICS INC-272,681-$1.77K00101
NEONEOGENOMICS INC-251,000-$2.06K00010
MYGNMYRIAD GENETICS INC-229,222-$20.57K01102
CMRXCHIMERIX INC-218,860-$1.21K00010
CPIXCUMBERLAND PHARMACEUTICALS-215,280-$5801102
VEEVVEEVA SYSTEMS INC-CLASS A-210,700-$9.81K00101
FOLDAMICUS THERAPEUTICS INC-196,400-$1.45K00010
PENPENUMBRA INC-186,500-$14.17K00010
RGENREPLIGEN CORP-186,100-$5.06K00101
DHRDANAHER CORP-168,713-$25.65K05308
INVAINNOVIVA INC-153,616-$7.01K00102
EDITEDITAS MEDICINE INC-128,400$2.97K00011
AXGNAXOGEN INC-126,900-$1.15K00010
ENTAENANTA PHARMACEUTICALS INC-126,629$59100101
CHECHEMED CORP-114,908-$15.21K00111
TBRGTRUBRIDGE INC-112,000-$3.00K00101
AMEDAMEDISYS INC-107,101-$6.34K00101
20 symbols with net change in reported shares from tracked managers.−15.8M−11.8M−7.9M−3.9M0.00Net change in reported shares (tracked managers)TEVAMRKLLYBAXZTSHCAUHSDVAUNHOPKABBVRMDPFEPHGEWBKDNVOEXELPTCTGERNSymbol

Frequently asked questions about Most sold healthcare stocks in Q4 2016

  • What are the most sold Healthcare stocks in Q4 2016?

    The most sold healthcare stocks in Q4 2016 are those with the largest decrease in reported share counts across tracked institutional investors compared to Q3 2016, based on SEC 13F filings.

  • Which healthcare stocks did institutional investors trimmed or exited the most in Q4 2016?

    Among the managers we track, net reductions were largest in companies such as TEVA PHARMACEUTICAL-SP ADR (TEVA), MERCK & CO. INC. (MRK), ELI LILLY & CO (LLY), based on aggregated 13F data.

  • How is institutional selling calculated?

    Selling is calculated by summing the net decrease in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q3 2016).

  • Does this include all institutional owners?

    These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.

  • Are these trades real-time?

    No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.